Oncorena Reports the First Patient Treatment of ONC175 (orellanine) in P-I/II Trial for Metastatic Renal Cancer
Shots:
- The first patient has been treated in the P-I/II trial evaluating the safety, tolerability, PK & antitumor effect of ONC175 in patients with metastatic renal cancer who are on dialysis at the Center for Clinical Cancer studies at Karolinska University Hospital, Stockholm, Sweden. The study is expected to be completed in August 2025
- Additionally, the patient followed up 4wk. after the infusion by IDMC recommending potential dose escalations. ONC175 is being developed as a potential cure for patients with metastatic renal cancer and dialysis-dependent renal failure
- ONC175 was found to be highly selective organ-targeted CT in preclinical studies with potent anti-tumor effects on metastatic renal cancer
Ref: Pharmiweb | Image: Oncorena
Related News:- Merck Reports P-III Trial (LITESPARK-005) Results of Welireg (belzutifan) for Patients with Advanced Renal Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
